Consensus $1.02B. Raises FY24 adjusted EBITDA view to $125M-$175M from $50M-$100M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent Biosolutions Adjusts Contract Terms and Preps Q1 Report
- Emergent BioSolutions Announces Restructuring and Cost-Saving Measures
- Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
- Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
- Emergent BioSolutions Announces Amendment to its Existing Credit Facility